Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021

SELL
$4.65 - $6.42 $6,486 - $8,955
-1,395 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$5.11 - $9.24 $536 - $970
-105 Reduced 7.0%
1,395 $9,000
Q3 2020

Nov 13, 2020

SELL
$4.7 - $12.06 $2,354 - $6,042
-501 Reduced 25.04%
1,500 $7,000
Q2 2020

Aug 14, 2020

BUY
$5.18 - $14.81 $10,365 - $29,634
2,001 New
2,001 $23,000

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.